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Interpreting Immune Mediator Dysbalance in 
Sepsis
To the Editor:
With great interest, we read the study published in a recent issue of Critical Care Medicine by Frencken et al (1). The study (1) assessed whether the bal-
ance of proinflammatory and anti-inflammatory cytokines 
would be associated with early or late mortality in critically 
ill patients with sepsis. Frencken et al (1) chose interleukin 
(IL)-6 and IL-10 as a marker for proinflammation and anti-
inflammation, respectively. Blood samples were obtained in 
708 patients at admission, days 2 and 4, and at ICU discharge. 
Data were analyzed in respect to 4-day, 28-day, and 1-year 
mortality. Frencken et al (1) found that both IL-6 and IL-10 
levels were independently associated with mortality, whereas 
the IL-6/IL-10 ratio was related to an increased risk for second-
ary infections but not to mortality. Frencken et al (1) conclude 
from their findings that the balance of respective inflamma-
tory mediators is not associated with mortality in patients with 
sepsis (1).
The new data underline previous findings that plasma 
concentrations of single cytokines, such as IL-6 and IL-10, 
are indeed associated with mortality in septic patients (2). 
However, the “balance” of the sepsis-induced host’s immune 
response can most likely not be reflected by analyzing a ratio 
of two pleiotropic cytokines. This might be true for sev-
eral reasons including the fact that cytokines 1) may both 
have “proinflammatory” and “anti-inflammatory” effector 
functions (e.g., IL-6); 2) originate not only from activated 
immune cells (e.g., IL-6 release by epithelial or endothelial 
cells following tissue trauma); 3) may be antagonized by cir-
culating regulatory molecules (e.g., soluble gp130 for IL-6, 
IL-1 receptor antagonist for IL-1β); 4) clearance rates may 
differ markedly making it difficult to compare plasma con-
centrations and local effector function; and 5) may be influ-
enced by levels of other pleiotropic cytokines (e.g., tumor 
necrosis factor-α, IL-12). Importantly, systemic cytokine lev-
els do thus not reflect the balance of the immune system or 
immune cell function and do not represent a specific type or 
phase of the hosts’ immune response. Even when repeatedly 
measured, systemic cytokine levels do therefore not ade-
quately portray the dynamic changes that are well-known 
to occur in sepsis and do not seem to reflect “immune bal-
ance” (3–5). Thus, assessment of an “immune balance” may 
require investigation of indices of cellular (and humoral) 
immune function.
predictors; this has not been made systematically previously 
to the best of our knowledge. Furthermore, we applied a pre-
defined American Clinical Neurophysiology Society nomen-
clature–based EEG scoring and tested it for both poor and 
good outcome outside a strict randomized controlled trial 
environment. In fact, in the study first describing it (3), the 
specificity for highly malignant patterns was 100%: false 
positive predictions of poor outcome were thus not found 
in that analysis.
In the discussion, we also already clearly acknowledged 
that reactivity has an imperfect interrater reliability (2), 
and we completely agree that this item needs to be broadly 
validated. By recommending nipple pinching, which has 
been meanwhile independently found to be the most 
sensitive stimulus by other groups (4), we feel we added 
practical valuable information. We routinely integrated 
background evaluation (and occurrence of epileptiform 
transients) in the assessments, and believe in any case that 
convergent findings from two centers with heterogeneous 
approaches support generalizability of our results. We also 
already acknowledged that recordings took place at het-
erogeneous timings (for instance, that was clearly the case 
for the routine EEGs: 17.9 ± 6.2 hr after CA); our intent 
was rather to point out that in resource-limited settings, 
a spot EEG during targeted temperature management and 
sedation, and the follow-up recording afterwards, contain 
valuable prognostic information, as already pointed out 
previously (5).
We agree with that heterogeneous recovery speed of brain 
function might influence results of the EEG assessment after 
targeted temperature management. Observations performed 
for the vast majority earlier than 24 hours following CA offer 
robust prediction to both outcome directions; this is valuable 
in clinical practice. Finally, given the (low) false positivity of 
EEG for poor outcome prediction, we cannot but reiterate the 
need for multimodal assessments in this setting (6).
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(4), various approaches to characterizing the balance of 
the host response have been advocated, such as transcrip-
tomic assessments (5), but also the balance of circulating 
inflammatory mediators (4, 6). Therefore, we measured a 
wide range of circulating mediators, several of which are 
well known to have either predominantly proinflammatory 
(interleukin [IL]-6, IL-8, and IL-1β) or anti-inflammatory 
(IL-10 and IL-13) action and studied the effects of media-
tor imbalance on mortality at different time points after 
sepsis onset. Subsequently, we did not look at a simple ratio 
of these markers (because this would ignore the “magni-
tude” of the overall response) but rather performed exten-
sive interaction analyses to explicitly model inflammatory 
mediator balance. As put forward by Pfortmueller et al (1), 
this approach arguably does not provide a fully compre-
hensive assessment of immune response. In this respect, a 
better understanding of the interdependence between the 
multitude of circulating inflammatory proteins and vari-
ous other tests of immunity is urgently needed. As it is 
unlikely that one irrefutable test of immune function will 
arise in the near future, combining multiple existing bio-
markers through structural equation modeling or latent 
class analysis could become an exciting new avenue for 
future research (7).
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The authors reply:
We thank Pfortmueller et al (1) for their interest in our study (2) and for their thoughtful remarks regarding the complexities of the host response 
in sepsis. How to assess whether a patient exhibits a hyper- 
or hypoinflammatory response to infection has been the 
subject of considerable debate yet is considered essential 
in the quest for new sepsis treatments (3). Because no sin-
gle biomarker has emerged as an indisputable measure of 
immune function (including human leukocyte antigen-DR 
expression on circulating myeloid antigen presenting cells) 
Immune “function” may best be assessed by direct analysis of 
cellular function (e.g., ex vivo cytokine production) or assess-
ment of antigen-presenting capability. In this context, standard-
ized assessment of monocyte human leukocyte antigen-DR 
(HLA-DR) on circulating myeloid antigen-presenting cells may 
be of particular interest as the expression of HLA-DR can be 
considered the “net result” of effector function of pleiotropic 
proinflammatory and anti-inflammatory mediators and was 
described to best reflect injury-associated immunosuppression, 
in particular in critically ill patients with sepsis (3–5).
The excellent new data provided by Frencken et al (1) allow 
for important new insights into the dynamics of cytokine 
mediators in sepsis and respective clinical usage, but caution 
seems advised in respect to drawing of conclusions on the sta-
tus or dynamics of the host’s immune response via exclusive 
analysis of circulating mediators.
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